Global Acute Myeloid Leukemia (AML) Therapeutic Sales Market Report 2016

November 2016 | 112 pages | ID: G809FAD94DCEN
QYResearch

Abstracts

Notes:

Sales, means the sales volume of Acute Myeloid Leukemia (AML) Therapeutic

Revenue, means the sales value of Acute Myeloid Leukemia (AML) Therapeutic

This report studies sales (consumption) of Acute Myeloid Leukemia (AML) Therapeutic in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering

• Ambit Biosciences Inc. (US)
• Aprea AB (Sweden)
• Astellas Pharma Inc. (Japan)
• Astex Pharmaceuticals, Inc. (US)
• Bio-Path Holdings, Inc. (US)
• BioSante Pharmaceuticals, Inc. (US)
• Celator Pharmaceuticals, Inc. (US)
• Celgene Corp. (US)
• Clavis Pharma ASA (Norway)
• Cyclacel Pharmaceuticals, Inc. (US)
• EpiCept Corp. (US)
• Genzyme Corporation (US)
• Lorus Therapeutics, Inc. (Canada)
• Novartis AG (Switzerland)
• Onconova Therapeutics, Inc. (US)

Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Acute Myeloid Leukemia (AML) Therapeutic in these regions, from 2011 to 2021 (forecast), like

• United States
• China
• Europe
• Japan

Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into

• Type I
• Type II
• Type III

Split by applications, this report focuses on sales, market share and growth rate of Acute Myeloid Leukemia (AML) Therapeutic in each application, can be divided into

• Application 1
• Application 2
• Application 3

Contents

Global Acute Myeloid Leukemia (AML) Therapeutic Sales Market Report 2016

1 ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC OVERVIEW

1.1 Product Overview and Scope of Acute Myeloid Leukemia (AML) Therapeutic
1.2 Classification of Acute Myeloid Leukemia (AML) Therapeutic
  1.2.1 Type I
  1.2.2 Type II
  1.2.3 Type III
1.3 Application of Acute Myeloid Leukemia (AML) Therapeutic
  1.3.1 Application
  1.3.2 Application
  1.3.3 Application
1.4 Acute Myeloid Leukemia (AML) Therapeutic Market by Regions
  1.4.1 United States Status and Prospect (2011-2021)
  1.4.2 China Status and Prospect (2011-2021)
  1.4.3 Europe Status and Prospect (2011-2021)
  1.4.4 Japan Status and Prospect (2011-2021)
1.5 Global Market Size (Value and Volume) of Acute Myeloid Leukemia (AML) Therapeutic (2011-2021)
  1.5.1 Global Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2021)
  1.5.2 Global Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2021)

2 GLOBAL ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC COMPETITION BY MANUFACTURERS, TYPE AND APPLICATION

2.1 Global Acute Myeloid Leukemia (AML) Therapeutic Market Competition by Manufacturers
  2.1.1 Global Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share of Key Manufacturers (2011-2016)
  2.1.2 Global Acute Myeloid Leukemia (AML) Therapeutic Revenue and Share by Manufacturers (2011-2016)
2.2 Global Acute Myeloid Leukemia (AML) Therapeutic (Volume and Value) by Type
  2.2.1 Global Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Type (2011-2016)
  2.2.2 Global Acute Myeloid Leukemia (AML) Therapeutic Revenue and Market Share by Type (2011-2016)
2.3 Global Acute Myeloid Leukemia (AML) Therapeutic (Volume and Value) by Regions
  2.3.1 Global Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Regions (2011-2016)
  2.3.2 Global Acute Myeloid Leukemia (AML) Therapeutic Revenue and Market Share by Regions (2011-2016)
2.4 Global Acute Myeloid Leukemia (AML) Therapeutic (Volume) by Application

3 UNITED STATES ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC (VOLUME, VALUE AND SALES PRICE)

3.1 United States Acute Myeloid Leukemia (AML) Therapeutic Sales and Value (2011-2016)
  3.1.1 United States Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2016)
  3.1.2 United States Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2016)
  3.1.3 United States Acute Myeloid Leukemia (AML) Therapeutic Sales Price Trend (2011-2016)
3.2 United States Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Manufacturers
3.3 United States Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Type
3.4 United States Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Application

4 CHINA ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC (VOLUME, VALUE AND SALES PRICE)

4.1 China Acute Myeloid Leukemia (AML) Therapeutic Sales and Value (2011-2016)
  4.1.1 China Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2016)
  4.1.2 China Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2016)
  4.1.3 China Acute Myeloid Leukemia (AML) Therapeutic Sales Price Trend (2011-2016)
4.2 China Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Manufacturers
4.3 China Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Type
4.4 China Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Application

5 EUROPE ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC (VOLUME, VALUE AND SALES PRICE)

5.1 Europe Acute Myeloid Leukemia (AML) Therapeutic Sales and Value (2011-2016)
  5.1.1 Europe Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2016)
  5.1.2 Europe Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2016)
  5.1.3 Europe Acute Myeloid Leukemia (AML) Therapeutic Sales Price Trend (2011-2016)
5.2 Europe Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Manufacturers
5.3 Europe Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Type
5.4 Europe Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Application

6 JAPAN ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC (VOLUME, VALUE AND SALES PRICE)

6.1 Japan Acute Myeloid Leukemia (AML) Therapeutic Sales and Value (2011-2016)
  6.1.1 Japan Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2016)
  6.1.2 Japan Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2016)
  6.1.3 Japan Acute Myeloid Leukemia (AML) Therapeutic Sales Price Trend (2011-2016)
6.2 Japan Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Manufacturers
6.3 Japan Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Type
6.4 Japan Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Application

7 GLOBAL ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC MANUFACTURERS ANALYSIS

7.1 Ambit Biosciences Inc. (US)
  7.1.1 Company Basic Information, Manufacturing Base and Competitors
  7.1.2 Acute Myeloid Leukemia (AML) Therapeutic Product Type, Application and Specification
    7.1.2.1 Type I
    7.1.2.2 Type II
  7.1.3 Ambit Biosciences Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
  7.1.4 Main Business/Business Overview
7.2 Aprea AB (Sweden)
  7.2.1 Company Basic Information, Manufacturing Base and Competitors
  7.2.2 112 Product Type, Application and Specification
    7.2.2.1 Type I
    7.2.2.2 Type II
  7.2.3 Aprea AB (Sweden) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
  7.2.4 Main Business/Business Overview
7.3 Astellas Pharma Inc. (Japan)
  7.3.1 Company Basic Information, Manufacturing Base and Competitors
  7.3.2 131 Product Type, Application and Specification
    7.3.2.1 Type I
    7.3.2.2 Type II
  7.3.3 Astellas Pharma Inc. (Japan) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
  7.3.4 Main Business/Business Overview
7.4 Astex Pharmaceuticals, Inc. (US)
  7.4.1 Company Basic Information, Manufacturing Base and Competitors
  7.4.2 Nov Product Type, Application and Specification
    7.4.2.1 Type I
    7.4.2.2 Type II
  7.4.3 Astex Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
  7.4.4 Main Business/Business Overview
7.5 Bio-Path Holdings, Inc. (US)
  7.5.1 Company Basic Information, Manufacturing Base and Competitors
  7.5.2 Product Type, Application and Specification
    7.5.2.1 Type I
    7.5.2.2 Type II
  7.5.3 Bio-Path Holdings, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
  7.5.4 Main Business/Business Overview
7.6 BioSante Pharmaceuticals, Inc. (US)
  7.6.1 Company Basic Information, Manufacturing Base and Competitors
  7.6.2 Million USD Product Type, Application and Specification
    7.6.2.1 Type I
    7.6.2.2 Type II
  7.6.3 BioSante Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
  7.6.4 Main Business/Business Overview
7.7 Celator Pharmaceuticals, Inc. (US)
  7.7.1 Company Basic Information, Manufacturing Base and Competitors
  7.7.2 Pharma & Healthcare Product Type, Application and Specification
    7.7.2.1 Type I
    7.7.2.2 Type II
  7.7.3 Celator Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
  7.7.4 Main Business/Business Overview
7.8 Celgene Corp. (US)
  7.8.1 Company Basic Information, Manufacturing Base and Competitors
  7.8.2 Product Type, Application and Specification
    7.8.2.1 Type I
    7.8.2.2 Type II
  7.8.3 Celgene Corp. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
  7.8.4 Main Business/Business Overview
7.9 Clavis Pharma ASA (Norway)
  7.9.1 Company Basic Information, Manufacturing Base and Competitors
  7.9.2 Product Type, Application and Specification
    7.9.2.1 Type I
    7.9.2.2 Type II
  7.9.3 Clavis Pharma ASA (Norway) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
  7.9.4 Main Business/Business Overview
7.10 Cyclacel Pharmaceuticals, Inc. (US)
  7.10.1 Company Basic Information, Manufacturing Base and Competitors
  7.10.2 Product Type, Application and Specification
    7.10.2.1 Type I
    7.10.2.2 Type II
  7.10.3 Cyclacel Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
  7.10.4 Main Business/Business Overview
7.11 EpiCept Corp. (US)
7.12 Genzyme Corporation (US)
7.13 Lorus Therapeutics, Inc. (Canada)
7.14 Novartis AG (Switzerland)
7.15 Onconova Therapeutics, Inc. (US)

8 ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC MAUFACTURING COST ANALYSIS

8.1 Acute Myeloid Leukemia (AML) Therapeutic Key Raw Materials Analysis
  8.1.1 Key Raw Materials
  8.1.2 Price Trend of Key Raw Materials
  8.1.3 Key Suppliers of Raw Materials
  8.1.4 Market Concentration Rate of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
  8.2.1 Raw Materials
  8.2.2 Labor Cost
  8.2.3 Manufacturing Process Analysis of Acute Myeloid Leukemia (AML) Therapeutic

9 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

9.1 Acute Myeloid Leukemia (AML) Therapeutic Industrial Chain Analysis
9.2 Upstream Raw Materials Sourcing
9.3 Raw Materials Sources of Acute Myeloid Leukemia (AML) Therapeutic Major Manufacturers in 2015
9.4 Downstream Buyers

10 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

10.1 Marketing Channel
  10.1.1 Direct Marketing
  10.1.2 Indirect Marketing
  10.1.3 Marketing Channel Development Trend
10.2 Market Positioning
  10.2.1 Pricing Strategy
  10.2.2 Brand Strategy
  10.2.3 Target Client
10.3 Distributors/Traders List

11 MARKET EFFECT FACTORS ANALYSIS

11.1 Technology Progress/Risk
  11.1.1 Substitutes Threat
  11.1.2 Technology Progress in Related Industry
11.2 Consumer Needs/Customer Preference Change
11.3 Economic/Political Environmental Change

12 GLOBAL ACUTE MYELOID LEUKEMIA (AML) THERAPEUTIC MARKET FORECAST (2016-2021)

12.1 Global Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue Forecast (2016-2021)
12.2 Global Acute Myeloid Leukemia (AML) Therapeutic Sales Forecast by Regions (2016-2021)
12.3 Global Acute Myeloid Leukemia (AML) Therapeutic Sales Forecast by Type (2016-2021)
12.4 Global Acute Myeloid Leukemia (AML) Therapeutic Sales Forecast by Application (2016-2021)

13 APPENDIX

Author List
Disclosure Section
Research Methodology
Data Source
China Disclaimer

List Of Tables

LIST OF TABLES AND FIGURES

Figure Picture of Acute Myeloid Leukemia (AML) Therapeutic
Table Classification of Acute Myeloid Leukemia (AML) Therapeutic
Figure Global Sales Market Share of Acute Myeloid Leukemia (AML) Therapeutic by Type in 2015
Figure Type I Picture
Figure Type II Picture
Table Applications of Acute Myeloid Leukemia (AML) Therapeutic
Figure Global Sales Market Share of Acute Myeloid Leukemia (AML) Therapeutic by Application in 2015
Figure Application 1 Examples
Figure Application 2 Examples
Figure United States Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2021)
Figure China Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2021)
Figure Europe Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2021)
Figure Japan Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2021)
Figure Global Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2021)
Figure Global Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2021)
Table Global Acute Myeloid Leukemia (AML) Therapeutic Sales of Key Manufacturers (2011-2016)
Table Global Acute Myeloid Leukemia (AML) Therapeutic Sales Share by Manufacturers (2011-2016)
Figure 2015 Acute Myeloid Leukemia (AML) Therapeutic Sales Share by Manufacturers
Figure 2016 Acute Myeloid Leukemia (AML) Therapeutic Sales Share by Manufacturers
Table Global Acute Myeloid Leukemia (AML) Therapeutic Revenue by Manufacturers (2011-2016)
Table Global Acute Myeloid Leukemia (AML) Therapeutic Revenue Share by Manufacturers (2011-2016)
Table 2015 Global Acute Myeloid Leukemia (AML) Therapeutic Revenue Share by Manufacturers
Table 2016 Global Acute Myeloid Leukemia (AML) Therapeutic Revenue Share by Manufacturers
Table Global Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Type (2011-2016)
Table Global Acute Myeloid Leukemia (AML) Therapeutic Sales Share by Type (2011-2016)
Figure Sales Market Share of Acute Myeloid Leukemia (AML) Therapeutic by Type (2011-2016)
Figure Global Acute Myeloid Leukemia (AML) Therapeutic Sales Growth Rate by Type (2011-2016)
Table Global Acute Myeloid Leukemia (AML) Therapeutic Revenue and Market Share by Type (2011-2016)
Table Global Acute Myeloid Leukemia (AML) Therapeutic Revenue Share by Type (2011-2016)
Figure Revenue Market Share of Acute Myeloid Leukemia (AML) Therapeutic by Type (2011-2016)
Figure Global Acute Myeloid Leukemia (AML) Therapeutic Revenue Growth Rate by Type (2011-2016)
Table Global Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Regions (2011-2016)
Table Global Acute Myeloid Leukemia (AML) Therapeutic Sales Share by Regions (2011-2016)
Figure Sales Market Share of Acute Myeloid Leukemia (AML) Therapeutic by Regions (2011-2016)
Figure Global Acute Myeloid Leukemia (AML) Therapeutic Sales Growth Rate by Regions (2011-2016)
Table Global Acute Myeloid Leukemia (AML) Therapeutic Revenue and Market Share by Regions (2011-2016)
Table Global Acute Myeloid Leukemia (AML) Therapeutic Revenue Share by Regions (2011-2016)
Figure Revenue Market Share of Acute Myeloid Leukemia (AML) Therapeutic by Regions (2011-2016)
Figure Global Acute Myeloid Leukemia (AML) Therapeutic Revenue Growth Rate by Regions (2011-2016)
Table Global Acute Myeloid Leukemia (AML) Therapeutic Sales and Market Share by Application (2011-2016)
Table Global Acute Myeloid Leukemia (AML) Therapeutic Sales Share by Application (2011-2016)
Figure Sales Market Share of Acute Myeloid Leukemia (AML) Therapeutic by Application (2011-2016)
Figure Global Acute Myeloid Leukemia (AML) Therapeutic Sales Growth Rate by Application (2011-2016)
Figure United States Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2016)
Figure United States Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2016)
Figure United States Acute Myeloid Leukemia (AML) Therapeutic Sales Price Trend (2011-2016)
Table United States Acute Myeloid Leukemia (AML) Therapeutic Sales by Manufacturers (2011-2016)
Table United States Acute Myeloid Leukemia (AML) Therapeutic Market Share by Manufacturers (2011-2016)
Table United States Acute Myeloid Leukemia (AML) Therapeutic Sales by Type (2011-2016)
Table United States Acute Myeloid Leukemia (AML) Therapeutic Market Share by Type (2011-2016)
Table United States Acute Myeloid Leukemia (AML) Therapeutic Sales by Application (2011-2016)
Table United States Acute Myeloid Leukemia (AML) Therapeutic Market Share by Application (2011-2016)
Figure China Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2016)
Figure China Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2016)
Figure China Acute Myeloid Leukemia (AML) Therapeutic Sales Price Trend (2011-2016)
Table China Acute Myeloid Leukemia (AML) Therapeutic Sales by Manufacturers (2011-2016)
Table China Acute Myeloid Leukemia (AML) Therapeutic Market Share by Manufacturers (2011-2016)
Table China Acute Myeloid Leukemia (AML) Therapeutic Sales by Type (2011-2016)
Table China Acute Myeloid Leukemia (AML) Therapeutic Market Share by Type (2011-2016)
Table China Acute Myeloid Leukemia (AML) Therapeutic Sales by Application (2011-2016)
Table China Acute Myeloid Leukemia (AML) Therapeutic Market Share by Application (2011-2016)
Figure Europe Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2016)
Figure Europe Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2016)
Figure Europe Acute Myeloid Leukemia (AML) Therapeutic Sales Price Trend (2011-2016)
Table Europe Acute Myeloid Leukemia (AML) Therapeutic Sales by Manufacturers (2011-2016)
Table Europe Acute Myeloid Leukemia (AML) Therapeutic Market Share by Manufacturers (2011-2016)
Table Europe Acute Myeloid Leukemia (AML) Therapeutic Sales by Type (2011-2016)
Table Europe Acute Myeloid Leukemia (AML) Therapeutic Market Share by Type (2011-2016)
Table Europe Acute Myeloid Leukemia (AML) Therapeutic Sales by Application (2011-2016)
Table Europe Acute Myeloid Leukemia (AML) Therapeutic Market Share by Application (2011-2016)
Figure Japan Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate (2011-2016)
Figure Japan Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate (2011-2016)
Figure Japan Acute Myeloid Leukemia (AML) Therapeutic Sales Price Trend (2011-2016)
Table Japan Acute Myeloid Leukemia (AML) Therapeutic Sales by Manufacturers (2011-2016)
Table Japan Acute Myeloid Leukemia (AML) Therapeutic Market Share by Manufacturers (2011-2016)
Table Japan Acute Myeloid Leukemia (AML) Therapeutic Sales by Type (2011-2016)
Table Japan Acute Myeloid Leukemia (AML) Therapeutic Market Share by Type (2011-2016)
Table Japan Acute Myeloid Leukemia (AML) Therapeutic Sales by Application (2011-2016)
Table Japan Acute Myeloid Leukemia (AML) Therapeutic Market Share by Application (2011-2016)
Table Ambit Biosciences Inc. (US) Basic Information List
Table Ambit Biosciences Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Ambit Biosciences Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Global Market Share (2011-2016)
Table Aprea AB (Sweden) Basic Information List
Table Aprea AB (Sweden) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Aprea AB (Sweden) Acute Myeloid Leukemia (AML) Therapeutic Global Market Share (2011-2016)
Table Astellas Pharma Inc. (Japan) Basic Information List
Table Astellas Pharma Inc. (Japan) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Astellas Pharma Inc. (Japan) Acute Myeloid Leukemia (AML) Therapeutic Global Market Share (2011-2016)
Table Astex Pharmaceuticals, Inc. (US) Basic Information List
Table Astex Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Astex Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Global Market Share (2011-2016)
Table Bio-Path Holdings, Inc. (US) Basic Information List
Table Bio-Path Holdings, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Bio-Path Holdings, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Global Market Share (2011-2016)
Table BioSante Pharmaceuticals, Inc. (US) Basic Information List
Table BioSante Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Figure BioSante Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Global Market Share (2011-2016)
Table Celator Pharmaceuticals, Inc. (US) Basic Information List
Table Celator Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Celator Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Global Market Share (2011-2016)
Table Celgene Corp. (US) Basic Information List
Table Celgene Corp. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Celgene Corp. (US) Acute Myeloid Leukemia (AML) Therapeutic Global Market Share (2011-2016)
Table Clavis Pharma ASA (Norway) Basic Information List
Table Clavis Pharma ASA (Norway) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Clavis Pharma ASA (Norway) Acute Myeloid Leukemia (AML) Therapeutic Global Market Share (2011-2016)
Table Cyclacel Pharmaceuticals, Inc. (US) Basic Information List
Table Cyclacel Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Cyclacel Pharmaceuticals, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Global Market Share (2011-2016)
Table EpiCept Corp. (US) Basic Information List
Table EpiCept Corp. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Figure EpiCept Corp. (US) Acute Myeloid Leukemia (AML) Therapeutic Global Market Share (2011-2016)
Table Genzyme Corporation (US) Basic Information List
Table Genzyme Corporation (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Genzyme Corporation (US) Acute Myeloid Leukemia (AML) Therapeutic Global Market Share (2011-2016)
Table Lorus Therapeutics, Inc. (Canada) Basic Information List
Table Lorus Therapeutics, Inc. (Canada) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Lorus Therapeutics, Inc. (Canada) Acute Myeloid Leukemia (AML) Therapeutic Global Market Share (2011-2016)
Table Novartis AG (Switzerland) Basic Information List
Table Novartis AG (Switzerland) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Novartis AG (Switzerland) Acute Myeloid Leukemia (AML) Therapeutic Global Market Share (2011-2016)
Table Onconova Therapeutics, Inc. (US) Basic Information List
Table Onconova Therapeutics, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Onconova Therapeutics, Inc. (US) Acute Myeloid Leukemia (AML) Therapeutic Global Market Share (2011-2016)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Acute Myeloid Leukemia (AML) Therapeutic
Figure Manufacturing Process Analysis of Acute Myeloid Leukemia (AML) Therapeutic
Figure Acute Myeloid Leukemia (AML) Therapeutic Industrial Chain Analysis
Table Raw Materials Sources of Acute Myeloid Leukemia (AML) Therapeutic Major Manufacturers in 2015
Table Major Buyers of Acute Myeloid Leukemia (AML) Therapeutic
Table Distributors/Traders List
Figure Global Acute Myeloid Leukemia (AML) Therapeutic Sales and Growth Rate Forecast (2016-2021)
Figure Global Acute Myeloid Leukemia (AML) Therapeutic Revenue and Growth Rate Forecast (2016-2021)
Table Global Acute Myeloid Leukemia (AML) Therapeutic Sales Forecast by Regions (2016-2021)
Table Global Acute Myeloid Leukemia (AML) Therapeutic Sales Forecast by Type (2016-2021)
Table Global Acute Myeloid Leukemia (AML) Therapeutic Sales Forecast by Application (2016-2021)